Navigation Links
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
Date:4/15/2008

s a stabilizer accounted for a disproportionate share of the total number.

Glycine, an amino acid, is used as a stabilizer. GAMMAGARD LIQUID does not contain sucrose.

GAMMAGARD LIQUID is made from human plasma. It may carry a risk of transmitting infectious agents, viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Components used in the packaging of this product are latex-free.

Thrombotic events have been reported in association with IGIV. Patients at risk may include those with a history of atherosclerosis, multiple cardiovascular risk factors, advanced age, impaired cardiac output, and/or known or suspected hyperviscosity, hypercoagulable disorders, and prolonged periods of immobilization.

IGIV products can contain blood group antibodies that may cause a positive direct antiglobulin reaction and, rarely, hemolysis.

Aseptic meningitis syndrome (AMS) has been reported to occur infrequently in association with IGIV treatment. Discontinuation of IGIV treatment has resulted in remission of AMS within several days without sequelae.

Various mild and moderate reactions, such as headache, fever, fatigue, chills, flushing, dizziness, urticaria, wheezing or chest tightness, nausea, vomiting, rigors, back pain, chest pain, muscle cramps, and changes in blood pressure may occur with infusions of Immune Globulin Intravenous (Human).

For full prescribing information, please visit http://www.gammagardliquid.com.

About Alzheimer's Disease

Alzheimer's disease is the most common form of dementia, a clinical condition, which involves the decline or loss of memory and other cognitive abilities. A progressive and ultimately fatal disease marked by severe brain tissue deterioration, Alzheimer's disease initially involves the parts of the brain that control thought, memory and language. The number of new Alzheimer's disease cases diagnosed
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... session that he will lead on “Stem Cells” at the ... 2015 in London. In the interview posted online ... respond to several questions on the current state of technologies ... toxicity, and future trends in the use of stem cells ...
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") (OTC: ... that its three Promissory Note holders, two of whom ... each in July 2014 for a total of $ ... converted into 3,500,001 restricted common shares. Notes were repayable ... Note and the coupon were convertible into common shares ...
(Date:9/29/2014)... Transparency Market Research, in its report ... HPPS, by Application - Cancer, Metabolic, CVS, CNS & ... Delivery) - Global Industry Analysis, Size, Share, Growth, Trends ... peptide therapeutics market was worth US$14.1 billion in 2011 ... at an 8.7% CAGR. , The two main types ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... MILWAUKEEThe growing popularity of digital music recorders, digital ... Brady Corporation 's recent acquisition of ID ... manufacturer and supplier of pressure sensitive die-cut components ... Brady Asia-Pacific Allan Klotsche, this acquisition, along with ...
... In order to surpass its original goal for life-long learning ... (ADL) Co-Laboratory has plans to move from University Research Park ... will make the move Sept. 1, a bit behind ... While delays in the approval processes are to blame for ...
... recently announced it received a Phase I small business ... Cancer Institute . , ,The grant, according to chief executive ... rapidly measure the activity of enzymes that are relevant to ... could develop a way to quickly quantify enzyme activity that ...
Cached Biology Technology:Brady continues growth through Asian acquisition 2Academic ADL Co-Lab moving to downtown Madison 2Academic ADL Co-Lab moving to downtown Madison 3
(Date:9/29/2014)... simple spheres of fluid, not normally considered capable of ... made droplets of alcohol move through water. In the ... able to move on your own to be ... organisms. But also non-living entities can be self-moving, report ... Chemical Technology in Prague, Czech Republic. , The researchers ...
(Date:9/29/2014)... This news release is available in French . ... 29th, 2014 - The number of days an expectant ... (1998) predicts the epigenetic profile of her child, a ... University Institute and McGill University have detected a distinctive ... aftermath of the massive Quebec ice storm. Five months ...
(Date:9/29/2014)... with Multiple Sclerosis (MS) were able to safely tolerate ... to a study published today in the journal ... is the first of its kind, was conducted by ... Celgene Corporation and collaborators at several other institutions. ... early signals in the data also suggested that a ...
Breaking Biology News(10 mins):Scientists make droplets move on their own 2Cells from placentas safe for patients with multiple sclerosis 2
... (Santa Barbara, Calif.) New research at UC Santa Barbara ... develop. The study is part of the campus,s expanding vision ... versions of The Proceedings of the National Academy of ... (IOVS). The scientists document how they used mice ...
... the collaboration of the Spanish Foundation for Biodiversity, the Charter ... the AZTI-Tecnalia R+D Centre will be studying the re-stocking of ... the months of May, June and July, respectively, in three ... gather the information needed to be able to manage the ...
... This release is available in German . ... research in Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) ... was taken by the appropriate Grants Committee in Bonn. The ... four and half years, during which time they will receive ...
Cached Biology News:UCSB scientists make strides in vision research 2A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10
NATIVE, ENZYME PORCINE TRYPSIN...
See product name for description....
Mycoplasma tested...
... Cloning Checker Kits provide two highly efficient ... without time-consuming plasmid preparation. By using the ... you need to do is to transfer ... from the transformation plates into the solutions ...
Biology Products: